Incidental COVID-19 on PET/CT imaging

Amin, Reshma; Grinblat, Leonard; Husain, Mansoor

doi:10.1503/cmaj.200831

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last few months, several case reports with incidental detection of COVID-19 on PET/CT have been issued worldwide 12 , 13 . However, a comprehensive study is still lacking in this regard.…”

Section: Introductionmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A Systematic Review of Incidental Detection of SARS-CoV-2 Pneumonia on PET Studies

Rafiee

Keshavarz

Katal

et al. 2021

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Purpose There have been several reports of the incidental detection of SARS-CoV-2 pneumonia on Positron Emission Tomography/Computed Tomography (PET/CT) studies, which represent the potential role of molecular imaging in detection and management of coronavirus disease 2019 (COVID-19). Here, we systematically review the value of PET/CT in this setting. Materials and Methods We conducted a systematic search on June 23, 2020, for PET studies with findings suggestive of COVID-19. Web of Science, PubMed, Scopus, EMBASE, and Google Scholar databases were used. Patients with at least one PET/CT imaging evaluation were included in the study. Results Fifty-two patients in 30 publications with a mean age of 60 ± 12.74 (age range; 27-87) were included in this study, of which 28(53.8%) were male, and 19(36.5%) were female. PET/CT was performed with 18 F-FDG for 49(94.2%), 18 F-choline for 2(3.8%), and 68 Ga-PSMA for 1 (1.9%) patients. The mean SUV max of pulmonary lesions with 18 F-FDG uptake was 4.9 ± 2.3. Moreover, 39(75%) cases had an underlying malignancy, including 18 different type of primary cancers and 6(11.5%) patients with metastatic disease. The most common pulmonary findings in PET/CT were bilateral hypermetabolic GGOs 39(75%), consolidation 18(34.6%), and interlobular thickening 4(7.6%). In addition, mediastinal 14(27%) and hilar 10(19.2%) lymph node involvement with increased metabolic activity were frequently identified. Conclusion Early diagnosis of SARS-CoV-2 pneumonia is not only crucial for both appropriate patient management but also helps to ensure appropriate post-exposure precautions are implemented for the department and hospital staff and those who have been in contact with the patient.

show abstract

Section: Introductionmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A Systematic Review of Incidental Detection of SARS-CoV-2 Pneumonia on PET Studies

Rafiee

Keshavarz

Katal

et al. 2021

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…Similarly, once a patient completely recovers from COVID-19 and remains well for at least 2 weeks after recovery, the patient may be considered eligible to undergo further immune-engaging therapies including CAR Tcell therapy (7). There are few reports of HL cases with COVID-19 infection (8)(9)(10)(11) this is the first report of the outcome of a relapsed HL patient after alloHCT, who was being treated brentuximab and subsequently develops COVID-19.…”

Section: Discussionmentioning

confidence: 98%

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

et al. 2021

View full text Add to dashboard Cite

First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes from this viral infection due to the immunosuppression brought about by the underlying cancer and the effects of therapy. We present a 55-year-old woman diagnosed with relapsed/refractory Hodgkin’s lymphoma (HL) who had been heavily pretreated with multiagent chemotherapy, autologous hematopoietic stem cell transplantation (autoHCT), allogeneic hematopoietic stem cell transplantation (alloHCT) and was complicated with EBV associated posttransplant lymphoproliferative disease (PTLD) and chronic graft-versus-host-disease (GVHD). The patient was recently treated with brentuximab and donor lymphocyte infusion (DLI) for relapse after alloHCT. She suffered from severe COVID-19 pneumonia and eventually succumbed to acute respiratory distress syndrome (ARDS) and multiorgan failure. Of note, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after alloHCT.

show abstract

“…There is evidence that chest CT imaging has a high sensitivity for COVID-19 diagnosis and may be more sensitive than the viral test, so it should be considered as a primary tool for detection [6,7]. Many studies have analyzed CT and follow-up CT scans of COVID-19 patients [6,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] as well as X-ray [26][27][28][29] and positron emission tomography (PET) [30][31][32][33]. However, there is a lack of rigorous studies that perform image analysis linked to clinical or laboratory findings, and COVID-ARC encourages data fusion, because it is likely that we will not understand COVID-19 well enough by studying just one data type.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 data sharing and collaboration

Duncan

2021

Communications in Information and Systems

View full text Add to dashboard Cite

There is an immediate need to study COVID-19, and the COVID-19 Data Archive (COVID-ARC) provides access to data along with user-friendly tools for researchers to perform analyses to better understand COVID-19 and encourage collaboration on this research. The COVID-19 pandemic has been spreading rapidly across the world, and there are still many unknowns about COVID-19. There is an urgent need for scientists around the world to work together to model the virus, study how the virus has changed and will change over time, understand how it spreads, and study transmission after vaccination. COVID-ARC can also prepare scientists for future pandemics by putting the infrastructure in place to enable researchers to aggregate data and perform analyses quickly in the event of an emergency. We have developed a platform of networked and centralized web-accessible data archives to store multimodal data related to COVID-19 and make them broadly available and accessible to the world-wide scientific community to expedite research in this area. COVID-ARC provides tools for researchers to visualize and analyze various types of data as well as a website with tools for training, announcements, virtual information sessions, and a knowledgebase wherein researchers post questions and receive answers from the community.

show abstract

Incidental COVID-19 on PET/CT imaging

Cited by 5 publications

References 5 publications

Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A Systematic Review of Incidental Detection of SARS-CoV-2 Pneumonia on PET Studies

Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A Systematic Review of Incidental Detection of SARS-CoV-2 Pneumonia on PET Studies

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

COVID-19 data sharing and collaboration

Contact Info

Product

Resources

About